Elena Tóthová

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

Jörge E. Cortes, Michele Baccarani, François Guilhot et al. · Journal of Clinical Oncology · 2009 · 285 citations · Full text

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

Heinz Ludwig, Roman Hájek, Elena Tóthová et al. · Blood · 2008 · 203 citations · Full text

Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study

Heinz Ludwig, Zdeněk Adam, Roman Hájek et al. · Journal of Clinical Oncology · 2010 · 146 citations · Full text

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

Jean‐Luc Harousseau, Giovanni Martinelli, W Wiktor-Jędrzejczak et al. · Blood · 2009 · 144 citations · Full text

High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.

Elena Tóthová, M Fričová, N Stecová et al. · PubMed · 2002 · 61 citations

Mixed-phenotype Acute Leukemia, Immunology, Cell Death +22